Brad Hirsch, MD, is the founder and CEO of SignalPath, a clinical trials technology solution that was recently acquired by Verily, an Alphabet company. Research sites and sponsors use SignalPath to run more efficient and effective clinical research studies, and under Brad’s leadership it has been widely adopted by leading health systems. Prior to SignalPath, Brad served as Senior Medical Director at Flatiron Health, a technology company focused on the use of clinical data for research in oncology. He is a medical oncologist and has been a principal investigator on multiple trials, ensuring that he has a deep understanding of the needs of clinical sites and research teams. Brad received his BA from the University of Pennsylvania, his MD from UT Southwestern and his MBA from Duke University’s Fuqua School of Business. He completed his fellowship in hematology and oncology at Duke University.